Skip to main content
Terug
MASI logo

Masimo Corporation

Datakwaliteit: 100%
Overbought
MASI
NASDAQ Healthcare Medical - Instruments & Supplies
€ 178,69
▲ € 0,25 (0,14%)
Marktkapitalisatie: 9,60B
Dagbereik
€ 177,84 € 178,80
52-Weeksbereik
€ 125,94 € 178,87
Volume
1.587.309
50D / 200D Gem.
€ 155,89 / € 150,88
Vorige Slotkoers
€ 178,44

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E -63,4 0,3
P/B 13,3 2,9
ROE % -17,1 3,7
Net Margin % -9,9 3,8
Rev Growth 5Y % 5,4 10,0
D/E 0,8 0,2

Koersdoel Analisten

Hold
€ 187,50 +4.9%
Low: € 180,00 High: € 200,00
Forward K/W
32,5
Forward WPA
€ 5,50
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,5 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 7,43
€ 7,37 – € 7,49
2 B 1
FY2029 € 7,43
€ 7,37 – € 7,49
1,9 B 1
FY2028 € 6,66
€ 6,37 – € 7,18
1,7 B 6

Belangrijkste Punten

Revenue grew 5,36% annually over 5 years — modest growth
Generating 197,80M in free cash flow
PEG of 0,89 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 32,46%
Capital efficient — spends only 1,27% of revenue on capex
ROIC of 18,32% — excellent capital efficiency

Groei

Revenue Growth (5Y)
5,36%
Revenue (1Y)-27,10%
Earnings (1Y)N/A
FCF Growth (3Y)455,93%

Kwaliteit

Return on Equity
-17,09%
ROIC18,32%
Net Margin-9,92%
Op. Margin20,49%

Veiligheid

Debt / Equity
0,78
Current Ratio2,49
Interest Coverage9,42

Waardering

P/E Ratio
-63,35
P/B Ratio13,31
EV/EBITDA31,99
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -27,10% Revenue Growth (3Y) -13,66%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5,36% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,53B Net Income (TTM) -151,50M
ROE -17,09% ROA -8,92%
Gross Margin 61,90% Operating Margin 20,49%
Net Margin -9,92% Free Cash Flow (TTM) 197,80M
ROIC 18,32% FCF Growth (3Y) 455,93%
Safety
Debt / Equity 0,78 Current Ratio 2,49
Interest Coverage 9,42 Dividend Yield 0,00%
Valuation
P/E Ratio -63,35 P/B Ratio 13,31
P/S Ratio 6,29 PEG Ratio 0,89
EV/EBITDA 31,99 Dividend Yield 0,00%
Market Cap 9,60B Enterprise Value 10,01B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,53B 2,09B 2,05B 2,04B 1,24B
Net Income -151,50M -304,90M 81,50M 143,50M 229,60M
EPS (Diluted) -2,80 -5,72 1,51 2,60 3,98
Gross Profit 945,20M 1,00B 1,00B 1,06B 808,40M
Operating Income 312,80M -266,70M 136,50M 210,00M 275,80M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,70B 2,63B 3,04B 3,21B 1,89B
Total Liabilities 977,70M 1,57B 1,68B 1,87B 336,80M
Shareholders' Equity 721,20M 1,05B 1,36B 1,34B 1,55B
Total Debt 559,30M 846,10M 970,00M 1,03B 32,70M
Cash & Equivalents 152,30M 177,60M 163,00M 202,90M 745,30M
Current Assets 926,00M 1,23B 1,23B 1,31B 1,24B
Current Liabilities 371,60M 617,70M 563,80M 630,00M 267,70M